Timing of G-CSF administration based on the circadian rhythm in patients with ovarian cancer

Am J Clin Oncol. 2002 Jun;25(3):289-90. doi: 10.1097/00000421-200206000-00018.

Abstract

The aim of this study was to determine the relationship between the timing of granulocyte colony-stimulating factor (G-CSF) administration and its efficacy in patients with chemotherapy-induced granulocytopenia. Twenty patients in whom chemotherapy-induced leukopenia developed after the first course were enrolled in this prospective study. Subjects were randomly divided in two groups according to G-CSF injection time as follows: at 7:00 am and 7:00 pm. Before the G-CSF injection, the plasma G-CSF level for all patients was significantly lower at 7:00 am than that at 7:00 pm. After the injection, plasma G-CSF level did not differ between the two groups. The nadir of the leukocyte was 2,554 +/- 379/mm3 (granulocyte 1,530 +/- 689) for the group injected at 7:00 am, and 2,300 +/- 426/mm3 (granulocyte 1,203 +/- 848) for the group injected at 7:00 pm. The duration of leukocytes less than 2,000/mm3 and granulocytes less than 1,000/mm3 were 2.8 +/- 1.8 days and 3.2 +/- 1.8 days, respectively. Those differences were not significant. The present study showed the circadian rhythm of G-CSF levels in patients with ovarian cancer with chemotherapy-induced granulocytopenia, but there was no remarkable difference depending on administration time.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Agranulocytosis / chemically induced
  • Agranulocytosis / prevention & control*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Circadian Rhythm*
  • Drug Administration Schedule
  • Female
  • Granulocyte Colony-Stimulating Factor / administration & dosage*
  • Humans
  • Middle Aged
  • Ovarian Neoplasms / drug therapy*
  • Prospective Studies

Substances

  • Granulocyte Colony-Stimulating Factor